key: cord-1039811-kf7bgqj1
authors: Kell, Douglas B.; Heyden, Eugene L.; Pretorius, Etheresia
title: The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria
date: 2020-05-28
journal: Front Immunol
DOI: 10.3389/fimmu.2020.01221
sha: 20c464e323a48f38722466594e62f47421056f9e
doc_id: 1039811
cord_uid: kf7bgqj1

Lactoferrin is a nutrient classically found in mammalian milk. It binds iron and is transferred via a variety of receptors into and between cells, serum, bile, and cerebrospinal fluid. It has important immunological properties, and is both antibacterial and antiviral. In particular, there is evidence that it can bind to at least some of the receptors used by coronaviruses and thereby block their entry. Of importance are Heparan Sulfate Proteoglycans (HSPGs) and the host receptor angiotensin-converting enzyme 2 (ACE2), as based on other activities lactoferrin might prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from attaching to the host cells. Lactoferrin (and more specifically enteric-coated LF because of increased bioavailability) may consequently be of preventive and therapeutic value during the present COVID-19 pandemic.

INTRODUCTION Lactoferrin (LF) or lactotransferrin has recently come under the spotlight, particularly with regards to the new coronavirus pandemic that started in 2019 . Diet and supplements support a well-functioning immune system, and favorably influence the body's ability to fight infection. Although LF is produced by the body itself, as a secretion by exocrine glands (such as maternal milk or tears) and secondary granules of human neutrophils (1) , it can also be taken as a supplement, where it then acts as nutraceutical or functional food. Our particular focus is on its role as an oral supplement. Here we also collate some of the evidence that shows how LF may be an important nutrient to support host immunity, including as an antibacterial and antiviral agent, but particularly with the current COVID-19 pandemic in mind.

We summarize what is already known about LF, including its immunological properties, as well as its antibacterial and antiviral activities. We also discuss how LF uses Heparan Sulfate Proteoglycans (HSPGs) on cell surfaces to facilitate entry. This is of particular importance to coronaviruses, as these viruses are considered to bind to the host cell by attaching first to HSPGs using them as preliminary docking sites on the host cell surface. LF is known to interfere with some of the receptors used by coronaviruses, it may thus contribute usefully to the prevention and treatment of SARS CoV-2 infections. In COVID-19 infection, LF may therefore have a role to play, not only sequestering iron and inflammatory molecules that are severely increased during the cytokine burst, but also possibly in assisting by occupying receptors and HSPGs. LF might also prevent virus accumulation by the host cell, as well as rolling activity and entering of the virus via the host receptor angiotensin-converting enzyme 2 (ACE2). It has been 20 years since the discovery of ACE2, and since its discovery it has been found to be expressed in numerous tissues, including the lungs and the cardiovascular system (2) . During 2020, there has been a renewed interest in this receptor, due to the interactions of novel coronaviruses and their interactions with ACE2 (3) (4) (5) . South and co-workers in 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5) . The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also been investigated (6, 7) . There is also interest in the therapeutic targeting of HSPGs, and Hondermarck and co-workers suggested that is seems an easy way to inhibit SARS-Cov-2 infectivity (8) .

Here we also suggest that LF might be used as both a preventive and therapeutic supplement in the COVID-19 pandemic, by preventing interactions between the virus and both HSPGs and possibly ACE2. We summarize the layout of this paper in Figure 1 .

Human LF is a cationic glycosylated protein consisting of 691 amino acids (9) folded into two globular lobes (80 kDa bi-lobal glycoprotein) (10) , that are connected by an α-helix (11, 12) . Bovine LF contains 689 amino acids (13) . LF was first discovered and isolated from bovine milk in 1939 (14) , and is a member of the transferrin family (60% amino acid sequence identity with serum transferrin) (11) . LF and transferrin have similar amino acid compositions, secondary structures (including their disulphide linkages), and tertiary structures, although they differ in terms of biological functions (11, 15, 16) (see Figure 2 ). There are also three different isoforms: LF-α is the iron-binding isoform, while LFβ and LF-g both have ribonuclease activity but do not bind iron (11, 17) . When it is iron-rich it is referred to hololactoferrin and when iron-free apolactoferrin (18). The tertiary structures of the two forms are significantly different: apolactoferrin is characterized by an open conformation of the N-lobe and a closed conformation of the C-lobe, while both lobes are closed in the hololactoferrin (18). Human LF and bovine LF possess high sequence homology and have very similar antibacterial, antifungal, antiviral, antiparasitic, anti-inflammatory, and immunomodulatory activities (19-21). Consequently, it is common to give the bovine form rather than say a recombinant human form as a supplement. Bovine LF is also deemed a "generally recognized as safe" substance by the Food and Drug Administration (FDA, USA), and is commercially available in large quantities (19). Due to its similarities to transferrin, which is the main iron transporting molecule in serum (22, 23), α-LF possesses iron binding capabilities (24, 25), and it can chelate two ferric irons (Fe 3+ ) (26). LF binds one ferric iron atom in each of its two lobes; however, an important attribute is that it does not release its iron, even at pH 3.5. This is of importance as this property assures iron sequestration in infected tissues where the pH is commonly acidic (27). In the context of its iron-binding capabilities, it means that when it binds ferric and siderophore-bound iron, it limits the availability of essential iron to microbes (27).

In healthy individuals, iron is largely intracellular and sequestered within ferritin or as a co-factor of cytochromes and FeS proteins, and as haem complexed to hemoglobin within erythrocytes. Circulating iron is rapidly bound by transferrin (28, 29). When erythrocytes lyse and hemoglobin or haem is released into the circulation, their hemoglobin is captured by haptoglobin, and haem by hemopexin (30). Here, circulating serum ferroxidase ceruloplasmin is of importance, as LF can bind to ceruloplasmin, such that a direct transfer of ferric iron between the two proteins is possible (31). A direct transfer of ferric iron from ceruloplasmin to lactoferrin prevents both the formation of potentially toxic hydroxyl radicals (32) and the utilization of iron by pathogenic bacteria. LF is therefore an important player in preventing bacteria from acquiring and sequestering iron, which [with the possible exception of Borrelia burgdorferi (33)]; they require for growth and virulence. LF also acts as biomarker, as it is commonly upregulated when the host is suffering from various kinds of disease. See Table 1 for selected references.

LF is thought to exert its main biological activities following interaction with receptors on target cells. There are in fact many LF receptors, though sometimes one is referred to as "the" lactoferrin receptor. They have been detected in multiple tissues and cell types including intestinal epithelial cells and lymphocytes (60, 61) . Receptors that bind LF include CD14 (62), LDL receptor-related protein-1 (LRP-1/CD91) (63-65) intelectin-1 (omentin-1) (66), Toll-like receptor 2 and 4 (TLR4) (67) and cytokine receptor 4 (CXCR4) (68) (see Table 2 ). Importantly, LF also binds to heparan sulfate proteoglycans (HSPGs), which are cell-surface and extracellular matrix macromolecules that are composed of a core protein decorated with covalently linked glycosaminoglycan (GAG) chains (86, 87, 98, 99) . See Table 2 . Different receptors express at vastly different levels in different tissues; thus intelectin-1 is really expressed only in the intestine (https:// www.proteinatlas.org/ENSG00000179914-ITLN1/tissue), while LRP1 is far more widely distributed https://www.proteinatlas. org/ENSG00000123384-LRP1/tissue. These multiple receptors arguably underpin the substantial and widespread effects that LF can induce, since only when multiple targets are hit simultaneously can one normally have major effects (103, 104) . FIGURE 1 | Overview of this review of lactoferrin (LF). We discuss (1) discovery and structure of LF; (2) LF membrane receptors and some of the bacteria, their products and viruses that might also bind to these receptors, (3) including how acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (causing COVID-19) may interact with host cells (see Figure 6 and Conclusion for a detailed discussion); (4) and how LF assists with host immunity. Diagram created with BioRender (www. biorender.com).

The entry of bacteria, bacterial products or viruses into host cells may also occur via some of these receptors. Such binding evokes signaling systems and pathways involving, amongst others, mitogen-activated protein kinase (MAPK) (105), NF-κB (106), activator protein 1 (AP-1) (107), and various interferon regulatory factors (IRFs) [for a comprehensive review see (108) ]. During infection, activation of these signaling pathways results in a cellular response that shares multiple cytoplasmic components, leading ultimately to the activation of a complex biomolecular network. Phosphorylation of relevant substrates (e.g., enzymes, microtubules, histones, and transcription factors) plays a crucial role in determining the host's cellular response (109) . Viruses (110, 111) , as well as bacteria (112) , interact with and bind to HSPGs, using this proteoglycan as entry into the cell (see also Figure 1 ). LF acts as an important element in host defense mechanisms by binding to these receptors, but also binding to HSPG on cells, since these are locations where binding to bacteria and their cell wall products as well as viruses occur. The membrane-penetrating peptide HIV-tat, released from HIVinfected cells, also enters surrounding cells using HSPGs (86, 98) . This binding capacity allows LF to compete with such molecules for receptor occupancy (113, 114) , and therefore plays 

Protecting neonates via breast milk (34-41)

LF in cervicovaginal mucosa and female reproductive tract; antibacterial, antifungal antiparasitic, antiviral (42) (43) (44) (45) LF in the airways (46, 47) Mucosal surfaces, allergen-induces skin infections (48) Neutrophil extracellular trap (NET) production (49) Saliva and its antimicrobial activities and iron binding (50) (51) (52) Saliva as biomarker for neurological diseases (53) (54) (55) Saliva as biomarker for periodontal disease and oral dryness (56) (57) (58) (59) a vital role in host immunity (20). LF can also serve to prevent nephrotoxicity, e.g., of cisplatin (115) .

Small molecules, including pharmaceutical drugs, require solute carriers of the SLC family (116) to effect their uptake (117) (118) (119) (120) (121) (122) (123) (124) . Lactoferrin, as a protein, is far too large to exploit such a route, and instead passes from the stomach via epithelial cells and into the blood using endocytosis (125, 126) , especially via Peyer's patches (127) , and when it is encapsulated ("enterically formulated") in liposomes (128) (129) (130) . This uptake then occurs mostly via the lymphatic rather than the portal circulation (131, 132) . LF can also enter, and be reabsorbed from, the bile (125) . Blood LF can further be transported to the CNS via cerebrospinal fluid (133, 134) and via the Blood Brain Barrier (63, 133) .

LF plays an important role in host defense, upon its release from the neutrophil (26). LF also enhances natural killer cell activity in immune defense (135) and can restrict the entry of the virus into host cells during infection. As part of the host's inflammatory response, leucocytes, including neutrophils, release LF from their granules, where it is normally stored. Activated Frontiers in Immunology | www.frontiersin.org FIGURE 3 | Bacterial binding to various receptors, e.g., Toll-like receptors 2 and 4 (TLR2 and 4), as well as complement receptors, leads to protein arginine deiminase 4 (PAD4) activation, followed by chromatin decondensation, hypercitrullination of histones 3 and 4 in the nucleus, and nuclear membrane disruption. Granules also release lactoferrin. Neutrophil Extracellular Traps (NETs) and their protein constituents (including lactoferrin) are released from the neutrophil. Adapted from Jorch and Kubes (142) and Law and Gray (143) . Bacteria are expelled and trapped in the NETs. Diagram created with BioRender (https://biorender.com/). neutrophils also release chromatin fibers, known as neutrophil extracellular traps (NETs), which trap and kill, amongst others, bacteria (1, 136) . These NETs likewise modulate both acute and chronic inflammation (137, 138) . NETs are also found in various autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus (139, 140) . Interestingly, 10 6 human neutrophils can release 15 µg of LF (26). In addition to DNA and histones, NET fibers contain extranuclear proteins and proteins such as elastase, myeloperoxidase (MPO), and LF (141) . LF may also serve as an intrinsic inhibitor of NETs release into the circulation, and may therefore be central in controlling NETs release (1). See 

One of the most well-known characteristics of LF is that it is antibacterial (19, [144] [145] [146] [147] [148] , antiviral (99, (149) (150) (151) , antifungal (152) (153) (154) , anti-inflammatory (26), and anti-carcinogenic (155).

Its ability to of limit iron availability to microbes is one of its crucial amicrobial properties. Bacteria have, however, developed various ways to sequester iron (156) . Figure 4 shows how bacteria acquire iron through receptor-mediated recognition of transferrin, hemopexin, hemoglobin, or hemoglobinhaptoglobin complexes and also LF (30). As well as binding it directly from the environment, bacterial siderophores can obtain iron by removing it from transferrin, lactoferrin, or ferritin (32). These siderophore-iron complexes are then recognized by receptors on the bacterium (30). Host innate immune functions are supported by the circulating protein, siderocalin, also known as Neutrophil gelatinase-associated lipocalin (NGAL), lipocalin2 or Lcn2 as it inhibits siderophore-mediated iron acquisition and release (30).

Although LF has various means to counteract bacteria as part of its immune function (131) , it is also capable of being hijacked to benefit the activities of bacteria. Thus, bacteria can also exploit LF by removing its bound ferric iron (19, 30). This process involves (1) synthesis of high-affinity ferric ion chelators by bacteria, (2) iron acquisition through LF or transferrin binding, mediated by bacterial-specific surface bacterial receptors, (3) or iron acquisition through bacterial reductases, which are able to reduce ferric to ferrous ions (19, [144] [145] [146] [147] [148] .

Several Gram-negative pathogens including members of the genera Neisseria and Moraxella have evolved two-component systems that can extract iron from the host LF and transferrin (157). N. meningitidis is a principal cause of bacterial meningitis in children. While the majority of pathogenic bacteria employ siderophores to chelate and scavenge iron (158) , Neisseria has evolved a series of protein transporters that directly hijack iron sequestered in host transferrin, lactoferrin, and hemoglobin (159) . The system consists of a membrane-bound transporter that extracts and transports iron across the outer membrane (TbpA for transferrin and LbpA for lactoferrin), and a lipoprotein that delivers iron-loaded lactoferrin/transferrin to the transporter (TbpB for transferrin and LbpB for lactoferrin) (157). LbpB binds the N-lobe of lactoferrin, whereas TbpB binds the C-lobe of transferrin (157). However, more than 90% of LF in human milk is in the form of apolactoferrin (160) , which competes with siderophilic bacteria for ferric iron, and disrupts the proliferation of these microbial and other pathogens. Similarly LF supplements may play an important role to counteract bacterial processes. LF is consequently a significant element of host defense (19), and its levels may vary in health and during disease. It is hence known to be a modulator of innate and adaptive immune responses (161) .

LF has strong antiviral activity against a broad spectrum of both naked and enveloped DNA and RNA viruses (99, (149) (150) (151) . LF inhibits the entry of viral particles into host cells, either by direct attachment to the viral particles or by blocking their cellular receptors (discussed in previous paragraphs) (149) . Some of the viruses that LF prevents from entering host cells e.g., Herpes simplex virus (162), human papillomavirus (163), human immunodeficiency virus (HIV) (164) , and rotavirus (165) . These viruses typically utilize common molecules on the cell membrane to facilitate their invasion into cells, including HSPGs (Figure 1) . HSPGs provide the first anchoring sites on the host cell surface, and help the virus make primary contact with these cells (99, 162) . HSPGs can be either membrane bound, or in secretory vesicles and in the extracellular matrix (86). It has been shown that LF is able to prevent the internalization of some viruses by binding to HSPGs (86).

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many COVID-19 patients develop acute respiratory distress syndrome (ARDS), which leads to pulmonary edema and lung failure, and have liver, heart, and kidney damages. These symptoms are associated with a cytokine storm (166, 167) (168) .

The 2003 SARS-CoV strain, that also causes severe acute respiratory syndrome, attaches to host cells via host receptor ACE2 (171) . This type I integral membrane protein receptor is a well-known receptor for respiratory viruses, and is abundantly expressed in tissues lining the respiratory tract (111) . During COVID-19 infection, SARS-CoV-2 also enters host cells via the ACE2 receptor (172) . ACE2 is highly expressed on human lung alveolar epithelial cells, enterocytes of the small intestine, and 

LF is a modulator of innate immune responses in the urinary tract and has potential application in novel therapeutic design for urinary tract infection (animal study) (188) Possible therapy against Candida albicans in the oral cavity (a hypothesis) (189) Protection against Chlamydia trachomatis (cell culture study) (190) Treatment of taste and smell abnormalities after chemotherapy (52) LF supplements and food with high levels of LF for oral health (99, 191) LF treatment of black stain associated with of iron metabolism disorders with lactoferrin (192) Aerosolized bovine LF counteracts infection, inflammation and iron dysbalance in a cystic fibrosis mouse model of Pseudomonas aeruginosa chronic lung infection (193) LF inhalations for lung health (194) LF for optimal skin moisture (195) the brush border of the proximal tubular cells of the kidney (99) . HSPGs are also one of the preliminary docking sites on the host cell surface and play an important role in the process of SARS-CoV cell entry (99) . There is no current confirmed information that SARS-CoV-2 binds to HSPGs, however, LF blocks the infection of SARS-CoV by binding to HSPGs (99). It is not presently known whether LF binds to ACE2, but it does bind to HSPGs (99) . Whether SARS-CoV-2 also enters host cells via HPSGs in the same way, as does (the 2003) SARS-CoV clearly warrants further investigation. Of particular interest, and in the context of this paper, is the set of interactions between SARS-CoV-2 and host platelets. This is of importance, as COVID-19 infection, can cause hyperinflammation due to a cytokine storm (166) . Pathogens like the influenza virus and Francisella tularensis, do trigger life-threatening cytokine storms (173) . Such a cytokine storm will significantly affect platelets, as platelets have many receptors where these inflammatory molecules may bind (173) (see Figure 5) . Circulating cytokines and inflammagens will hyperactivate platelets, causing low platelet count (thrombocytopenia), and a significant chance of hypercoagulation. Thrombocytopenia is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus serves as clinical indicator of worsening illness during hospitalization (174, 175) . Patients with type 2 diabetes are also particularly prone to increased levels of circulating inflammatory cytokines and hypercoagulation (76) . COVID-19 patients without other comorbidities but with diabetes are at higher risk of severe pneumonia, excessive uncontrolled inflammatory responses and a hypercoagulable state (176) . Guo and co-workers in 2020 also found that serum levels of IL-6, C-reactive protein, serum ferritin, and D-dimer, were significantly higher in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of the patient with COVID-19 (140) . Acute pulmonary embolism has also been reported in COVID-19 infection (177) . Focal accumulation of activated platelets within the oedematous area ex vivo correlated well with the size of the pulmonary embolism (178) . Interestingly, anticoagulant therapy, mainly with (intravenous) heparin (and mainly with low molecular weight heparin, LMWH), appears to be associated with better prognosis in severe COVID-19 patients (179) .

In COVID-19 infection, LF may have a role to play in not only sequestering iron and inflammatory molecules that are severely increased during the cytokine burst, but also possibly in assisting in occupying receptors and HSPGs to prevent virus binding. Receptor occupancy is an important characteristic of LF, when taken as supplement. Furthermore, it may assist in preventing thrombocytopenia, and hypercoagulation, both prominent features of COVID-19 infection.

There is little doubt that oral LF can be of health benefit to the host, and while it is not considered to be absolutely necessary for mammalian life (so it is not a vitamin), it is reasonable to class it as a nutraceutical along with a variety of other molecules such as those mentioned in various papers (180, 181) . As a nutraceutical, the bioavailability of LF would clearly be an important consideration in its use for the prevention or treatment of COVID-19. Enteric coating of LF capsules has been proposed as a measure to maximize the uptake of LF by the receptors located in the brush-border of the small intestine (182) . Enteric coating allows LF release some distance from LF-degrading pepsin activities in the stomach, allowing it to remain intact, in the form capable of binding small intestinal LF receptors for uptake and eventual transfer into the systemic circulation (182) . In a rodent study, the "absorption" of entericformulated LF was approximately 10-fold higher than that of regular LF introduced into the stomach of experimental animals (128) . In view of these investigations, the authors of this paper regard enteric-coated LF as superior to regular LF supplements with respect to bioavailability and potential application for the prevention or therapy for coronaviruses such as the SARS-Cov-2 involved in COVID-19.

There is considerable LF availability in various forms and sources. Table 3 shows some of the sources and the references to research where it has been used to treat various conditions.

Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99) . HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99) . The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99) . LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5) (6) (7) (8) . LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed.

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Another recent review (196) has also highlighted the potential utility of lactoferrin as an antiviral.

EP wrote the paper. DK edited and wrote part of the paper. EH provided clinical input and edited the paper. All authors approved submission of the paper. 

Lactoferrin suppresses neutrophil extracellular traps release in inflammation

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19

ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19

COVID-19, ACE2, and the cardiovascular consequences

Current status of potential therapeutic candidates for the COVID-19 crisis

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

The role of growth factor receptors in viral infections: an opportunity for drug repurposing against emerging viral diseases such as COVID-19?

Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins

Lactoferrin, a bird's eye view

Studying lactoferrin N-glycosylation

Selective deglycosylation of lactoferrin to understand glycans' contribution to antimicrobial activity of lactoferrin

Threedimensional structure of diferric bovine lactoferrin at 2.8 A resolution

Compte Rendu des Travaux du Laboratoire de Carlsberg. Copenhague: The Proteins in Whey

Molecular weight, single-chain structure and amino acid composition of human lactoferrin

Amino acid sequence of cysteic peptides of lactoferrin and demonstration of similarities between lactoferrin and transferrin

Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that 39

Bioactive proteins in human milk: health, nutrition, and implications for infant formulas

Lactoferrin level in breast milk: a study of 248 samples from eight regions in China

Role of lactobacilli and lactoferrin in the mucosal cervicovaginal defense

Innate host defense of human vaginal and cervical mucosae

New sensitive method for the measurement of lysozyme and lactoferrin for the assessment of innate mucosal immunity. Part I: time-resolved immunofluorometric assay in serum and mucosal secretions

A multiplexed assay to detect antimicrobial peptides in biological fluids and cell secretions

Antimicrobial peptides in the airway

Airway surface liquid from smokers promotes bacterial growth and biofilm formation via iron-lactoferrin imbalance

Lactoferrin and host defense

Neutrophil extracellular traps and its implications in inflammation: an overview. Front Immunol

The role of natural salivary defences in maintaining a healthy oral microbiota

Salivary changes before and after hematopoietic stem cell transplantation: a systematic review

Effect of lactoferrin on taste and smell abnormalities induced by chemotherapy: a proteome analysis

Said Sadier N. Salivary biomarkers for the diagnosis and monitoring of neurological diseases

Biomarkers for Alzheimer's disease in saliva: a systematic review

Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

Application of lactoferrin and α1-antitrypsin in gingival retention fluid to diagnosis of periodontal disease

Levels of the antimicrobial proteins lactoferrin and chromogranin in the saliva of individuals with oral dryness

Elevated levels of salivary lactoferrin, a marker for chronic periodontitis?

Concentrations of thiocyanate, hypothiocyanite, 'free' and 'total' lysozyme, lactoferrin and secretory IgA in resting and stimulated whole saliva of children aged 12-14 years and the relationship with plaque accumulation and gingivitis

Apo-and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells

Mammalian lactoferrin receptors: structure and function

The multifunctional glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a novel macrophage lactoferrin receptor

Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier

The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells

Role of LRP1 and ERK and cAMP signaling pathways in lactoferrininduced lipolysis in mature rat adipocytes

Recombinant human intelectin binds bovine lactoferrin and its peptides

Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2-into M1-like phenotype

Role of CXC chemokine receptor type 4 as a lactoferrin receptor

Role of vitamin D in Amyloid clearance via LRP-1 upregulation in Alzheimer's disease: a potential therapeutic target?

Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes

Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia

Adipose tissue-derived omentin-1 function and regulation

Endothelial TLR4 and the microbiome drive cerebral cavernous malformations

Platelets at the crossroads of thrombosis, inflammation and haemolysis

Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis

Platelets as potent signaling entities in type 2 diabetes mellitus

Role of TLR4 (Toll-Like receptor 4) in N1/N2 neutrophil programming after stroke

A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection

Periodontopathogens induce expression of CD40L on human platelets via TLR2 and TLR4

Human milk components modulate Toll-like receptor-mediated inflammation

Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway

CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease

Mobilization of CD8(+) T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer

Anti-CD14 antibody-treated neutrophils respond to lps: possible involvement of CD14 upregulated by anti-CD14 antibody binding

Macrophage CD14 impacts immune defenses against influenza virus in allergic hosts

Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells

Epigallocatechin-3-gallate rescues LPS-impaired adult hippocampal neurogenesis through suppressing the TLR4-NF-κB signaling pathway in mice

Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1

Neuronal clearance of amyloid-beta by endocytic receptor LRP1

Stereoelectronic effects impact glycan recognition

On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death

Obesity, diabetes, and the gut microbiome: an updated review

Herpes simplex virus type 2 infection triggers AP-1 transcription activity through TLR4 signaling in genital epithelial cells

Molecular mechanism of HIV-1 entry

The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, HIV infections

H7N9 influenza A virus activation of necroptosis in human monocytes links innate and adaptive immune responses

Cellular uptake of the tat protein from human immunodeficiency virus

Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

Membrane protein of human coronavirus NL63 is responsible for interaction with the adhesion receptor

Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? Viruses

Canine respiratory coronavirus, bovine coronavirus, and human coronavirus OC43: receptors and attachment factors

Strategies for manipulating metabolic fluxes in biotechnology

The role of modeling in systems biology

6-Bromoindirubin-3'-oxime suppresses LPS-induced inflammation via inhibition of the TLR4/NF-κB and TLR4/MAPK signaling pathways

Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose

Inhibition of the TIRAP-c-Jun interaction as a therapeutic strategy for AP1-mediated inflammatory responses

Neutrophil cell surface receptors and their intracellular signal transduction pathways

Heparan sulfate proteoglycans: structure, protein interactions and cell signaling

Heparan sulfate proteoglycan as a cell-surface endocytosis receptor

Entry of human coronavirus NL63 into the cell

Heparan sulfate modulates neutrophil and endothelial function in antibacterial innate immunity

Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein

Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process

Protective effect of lactoferrin on cisplatin-induced nephrotoxicity in rats

The ABCs of membrane transporters in health and disease (SLC series): introduction

Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?

What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible?

The transporter-mediated cellular uptake of pharmaceutical drugs is based on their metabolite-likeness and not on their bulk biophysical properties: towards a systems pharmacology

The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so

Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion

The RESOLUTE consortium: unlocking SLC transporters for drug discovery

A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs

Characteristic transport of lactoferrin from the intestinal lumen into the bile via the blood in piglets

Cellular uptake and release of intact lactoferrin and its derivatives in an intestinal enterocyte model of Caco-2 cells

Characteristics of lactoferrin receptor in bovine intestine: higher binding activity to the epithelium overlying Peyer's patches

Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats

Liposomalization of lactoferrin enhanced it's anti-inflammatory effects via oral administration

Liposomalization of lactoferrin enhanced its antitumoral effects on melanoma cells

Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats

No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats

Trans-endothelial and trans-epithelial transfer of lactoferrin into the brain through BBB and BCSFB in adult rats

Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves

Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome

Neutrophil extracellular traps kill bacteria

Neutrophils and NETs in modulating acute and chronic inflammation

Neutrophils and neutrophil extracellular traps orchestrate initiation and resolution of inflammation

Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review

Neutrophil extracellular traps in immunity and disease

Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans

An emerging role for neutrophil extracellular traps in noninfectious disease

Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review

Siderophores for molecular imaging applications

The lactoferrin receptor complex in Gram negative bacteria

Iron acquisition through the bacterial transferrin receptor

Bacterial heme sources: the role of heme, hemoprotein receptors and hemophores

Extracellular heme uptake and the challenge of bacterial cell membranes

Potential lactoferrin activity against pathogenic viruses

Bovine lactoferrin inhibits dengue virus infectivity by interacting with heparan sulfate, lowdensity lipoprotein receptor, and DC-SIGN

Bovine lactoferrin activity against Chikungunya and Zika viruses

The antifungal activity of lactoferrin and its derived peptides: mechanisms of action and synergy with drugs against fungal pathogens. Front Microbiol

Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis

Antifungal mechanism of action of lactoferrin: identification of H+-ATPase (P3A-type) as a new apoptoticcell membrane receptor

Lactoferrin: structure, function, denaturation and digestion

The structure of lactoferrin-binding protein B from Neisseria meningitidis suggests roles in iron acquisition and neutralization of host defences

Iron availability and infection

Iron acquisition systems in the pathogenic Neisseria

Iron in human milk

Overview of lactoferrin as a natural immune modulator

Heparan sulfate proteoglycan as a plasma membrane carrier

Lactoferrin inhibits human papillomavirus binding and uptake in vitro

Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection

Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection

COVID-19: consider cytokine storm syndromes and immunosuppression

To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin?

TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib

IL-22: there is a gap in our knowledge

Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS)

Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Targeting the "cytokine storm" for therapeutic benefit

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis

Diabetes is a risk factor for the progression and prognosis of COVID-19

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Molecular imaging of activated platelets allows the detection of pulmonary embolism with magnetic resonance imaging

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Prolonging healthy aging: longevity vitamins and proteins

The biology of ergothioneine, an antioxidant nutraceutical

Effects of enteric-coated lactoferrin supplementation on the immune function of elderly individuals: a randomised, double-blind, placebo-controlled trial

Identification of the bactericidal domain of lactoferrin

Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants

Consumption of transgenic cows' milk containing human lactoferrin results in beneficial changes in the gastrointestinal tract and systemic health of young pigs

Large-scale production of recombinant human lactoferrin from high-expression, marker-free transgenic cloned cows. Sci Rep

Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota

Augmentation of urinary lactoferrin enhances host innate immune clearance of uropathogenic Escherichia coli

The potential management of oral candidiasis using anti-biofilm therapies

Lactobacilli-lactoferrin interplay in Chlamydia trachomatis infection

Effects of lactoferrin and lactoperoxidase-containing food on the oral hygiene status of older individuals: a randomized, double blinded, placebo-controlled clinical trial

The treatment of black stain associated with of iron metabolism disorders with lactoferrin: a litterature search and two case studies

Aerosolized bovine lactoferrin counteracts infection, inflammation and iron dysbalance in a cystic fibrosis mouse model of Pseudomonas aeruginosa chronic lung infection

Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin

Effects of lactoferrin on subjective skin conditions in winter: a preliminary, randomized, double-blinded, placebo-controlled trial

Viral infections: lactoferrin, a further arrow in the quiver of prevention

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Kell, Heyden and Pretorius. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.